These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Clinical trials of propentofylline in vascular dementia. European/Canadian Propentofylline Study Group. Kittner B Alzheimer Dis Assoc Disord; 1999; 13 Suppl 3():S166-71. PubMed ID: 10609697 [TBL] [Abstract][Full Text] [Related]
23. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints. Jenkins M; Stone A; Jennison C Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327 [TBL] [Abstract][Full Text] [Related]
24. Designing phase III or IV trials for vaccines: choosing between individual or cluster randomised trial designs. Vaucher P Vaccine; 2009 Mar; 27(13):1928-31. PubMed ID: 19368773 [TBL] [Abstract][Full Text] [Related]
25. Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases. van der Lee JH; Wesseling J; Tanck MW; Offringa M J Clin Epidemiol; 2008 Apr; 61(4):324-30. PubMed ID: 18313556 [TBL] [Abstract][Full Text] [Related]
26. Design of randomized controlled trials. Stanley K Circulation; 2007 Mar; 115(9):1164-9. PubMed ID: 17339574 [No Abstract] [Full Text] [Related]
36. Have randomized controlled trials of neuroprotective drugs been underpowered? An illustration of three statistical principles. Samsa GP; Matchar DB Stroke; 2001 Mar; 32(3):669-74. PubMed ID: 11239185 [TBL] [Abstract][Full Text] [Related]
37. Ethics and practice: alternative designs for phase III randomized clinical trials. Palmer CR; Rosenberger WF Control Clin Trials; 1999 Apr; 20(2):172-86. PubMed ID: 10227416 [TBL] [Abstract][Full Text] [Related]